Association of STAT3 Common Variations with Obesity and Hypertriglyceridemia: Protective and Contributive Effects
Abstract
:1. Introduction
2. Results
Variable | All | Overweight | General Obesity | Central Obesity | Healthy Weight | p a | |
---|---|---|---|---|---|---|---|
Gender | Male (%) | 702 (40.3) b | 291 (61.7) | 88 (77.2) | 140 (59.1) | 227 (26.1) | <0.005 |
Female (%) | 1040 (59.7) b | 181 (38.3) | 26 (22.8) | 97 (40.9) | 644 (73.9) | ||
Age (years) | 37.40 ± 10.97 (18–85) | 41.19 ± 10.82 | 43.63 ± 11.00 | 43.53 ± 11.17 | 34.67 ± 9.53 | <0.005 | |
BMI (kg/m2) | 23.03 ± 3.36 (15.12–37.09) | 25.69 ± 1.10 | 30.05 ± 2.15 | 27.45 ± 2.66 | 21.33 ± 1.50 | <0.005 | |
FG (mmol/L) | 4.88 ± 0.79 (3.0–14.0) | 5.05 ± 0.82 | 5.32 ± 1.11 | 5.20 ± 0.92 | 4.73 ± 0.54 | <0.005 | |
TG (mmol/L) | 1.29 ± 1.09 (0.25–16.59) | 1.72 ± 1.38 | 2.08 ± 1.50 | 1.92 ± 1.53 | 0.96 ± 0.69 | <0.005 | |
TC (mmol/L) | 4.81 ± 0.96 (2.42–9.71) | 5.09 ± 0.98 | 5.02 ± 1.04 | 5.03 ± 0.96 | 4.63 ± 0.88 | <0.005 | |
HDL (mmol/L) | 1.76 ± 0.43 (0.73–3.42) | 1.60 ± 0.38 | 1.43 ± 0.32 | 1.50 ± 0.33 | 1.88 ± 0.41 | <0.005 | |
LDL (mmol/L) | 2.46 ± 0.72 (0.68–5.59) | 2.71 ± 0.75 | 2.69 ± 0.73 | 2.66 ± 0.68 | 2.30 ± 0.64 | <0.005 | |
SBP (mm Hg) | 114.91 ± 15.62 (78–190) | 122.03 ± 15.40 | 127.78 ± 15.77 | 125.33 ± 15.03 | 110.57 ± 13.40 | <0.005 | |
DBP (mm Hg) | 72.34 ± 10.16 (41–125) | 76.33 ± 10.40 | 80.85 ± 10.52 | 78.68 ± 10.34 | 69.57 ± 8.62 | <0.005 | |
WC (cm) | 75.60 ± 10.67 (47–116) | 84.24 ± 6.69 | 94.99 ± 7.89 | 91.58 ± 6.89 | 70.81 ± 6.43 | <0.005 |
Variable | rs1053005 | p | rs957970 | p | ||||
---|---|---|---|---|---|---|---|---|
AA | AG | GG | TT | CT | CC | |||
BMI (kg/m2) | 23.23 ± 3.54 | 22.88 ± 3.25 | 22.76 ± 2.91 | 0.013 | 23.10 ± 3.44 | 23.08 ± 3.35 | 22.71 ± 3.19 | 0.41 |
FG (mmol/L) | 4.87 ± 0.78 | 4.89 ± 0.76 | 4.95 ± 0.92 | 0.62 | 4.86 ± 0.74 | 4.90 ± 0.77 | 4.90 ± 0.92 | 0.54 |
TG (mmol/L) | 1.24 ± 0.87 | 1.33 ± 1.27 | 1.39 ± 1.17 | 0.25 | 1.20 ± 0.81 | 1.38 ± 1.30 | 1.26 ± 1.01 | 0.007 |
TC (mmol/L) | 4.81 ± 0.94 | 4.81 ± 0.96 | 4.80 ± 1.04 | 0.91 | 4.82 ± 0.92 | 4.82 ± 0.98 | 4.77 ± 0.98 | 0.69 |
HDL (mmol/L) | 1.77 ± 0.43 | 1.75 ± 0.42 | 1.72 ± 0.45 | 0.36 | 1.78 ± 0.43 | 1.74 ± 0.42 | 1.76 ± 0.44 | 0.46 |
LDL (mmol/L) | 2.46 ± 0.72 | 2.45 ± 0.70 | 2.46 ± 0.76 | 0.95 | 2.47 ± 0.70 | 2.46 ± 0.72 | 2.42 ± 0.73 | 0.52 |
WC (cm) | 76.20 ± 11.06 | 75.05 ± 10.40 | 75.23 ± 9.94 | 0.02 | 75.74 ± 10.70 | 75.76 ± 10.69 | 74.82 ± 10.58 | 0.90 |
Variable | Genotype | Case | Control | OR Crude | 95% CI | p | OR Adjusted | 95% CI | p a |
---|---|---|---|---|---|---|---|---|---|
N (%) | N (%) | ||||||||
Overweight | AA | 217 (46.0) | 391 (44.9) | 1.00 | 1.00 | ||||
AG | 206 (43.6) | 384 (44.1) | 0.97 | 0.76–1.23 | 0.78 | 0.95 | 0.73–1.23 | 0.69 | |
GG | 49 (10.4) | 96 (11.0) | 0.92 | 0.63–1.35 | 0.67 | 0.80 | 0.52–1.22 | 0.29 | |
Dominant | 0.96 | 0.76–1.20 | 0.70 | 0.91 | 0.71–1.17 | 0.48 | |||
A | 640 (67.8) | 1166 (66.9) | 1.00 | ||||||
G | 304 (32.2) | 576 (33.1) | 0.96 | 0.81–1.14 | 0.65 | ||||
General Obesity | AA | 70 (61.4) | 391 (44.9) | 1.00 | 1.00 | ||||
AG | 36 (31.6) | 384 (44.1) | 0.52 | 0.34–0.80 | 0.003 | 0.49 | 0.30–0.78 | 0.003 | |
GG | 8 (7.0) | 96 (11.0) | 0.47 | 0.22–1.00 | 0.05 | 0.40 | 0.17–0.93 | 0.034 | |
Dominant | 0.51 | 0.34–0.76 | 0.001 | 0.47 | 0.30–0.73 | 0.001 | |||
A | 176 (77.2) | 1166 (66.9) | 1.00 | ||||||
G | 52 (22.8) | 576 (33.1) | 0.60 | 0.43–0.84 | 0.002 | ||||
Hypertriglyceridemia | AA | 155 (45.1) | 611 (46.8) | 1.00 | 1.00 | ||||
AG | 150 (43.6) | 561 (42.9) | 1.05 | 0.82–1.36 | 0.68 | 1.04 | 0.79–1.37 | 0.78 | |
GG | 39 (11.3) | 135 (10.3) | 1.14 | 0.77–1.70 | 0.52 | 1.04 | 0.67–1.59 | 0.87 | |
Dominant | 1.07 | 0.84–1.36 | 0.58 | 1.04 | 0.80–1.34 | 0.78 | |||
A | 460 (66.9) | 1783 (68.2) | 1.00 | ||||||
G | 228 (33.1) | 831 (31.8) | 1.06 | 0.89–1.28 | 0.50 | ||||
Borderline-Hypercholesterolemia | AA | 103 (45.8) | 529 (46.4) | 1.00 | 1.00 | ||||
AG | 104 (46.2) | 490 (43.0) | 1.09 | 0.81–1.47 | 0.57 | 1.08 | 0.80–1.46 | 0.63 | |
GG | 18 (8.0) | 120 (10.6) | 0.77 | 0.45–1.32 | 0.34 | 0.73 | 0.42–1.27 | 0.27 | |
Dominant | 1.03 | 0.77–1.37 | 0.86 | 1.01 | 0.76–1.36 | 0.93 | |||
A | 310 (68.9) | 1548 (68.0) | 1.00 | ||||||
G | 140 (31.1) | 730 (32.0) | 0.96 | 0.77–1.20 | 0.70 | ||||
Hypercholesterolemia | AA | 134 (46.7) | 529 (46.4) | 1.00 | 1.00 | ||||
AG | 117 (40.8) | 490 (43.0) | 0.94 | 0.72–1.24 | 0.68 | 0.91 | 0.68–1.21 | 0.50 | |
GG | 36 (12.5) | 120 (10.6) | 1.18 | 0.78–1.80 | 0.43 | 1.10 | 0.70–1.71 | 0.68 | |
Dominant | 0.99 | 0.76–1.28 | 0.94 | 0.95 | 0.72–1.24 | 0.69 | |||
A | 385 (67.1) | 1548 (68.0) | 1.00 | ||||||
G | 189 (32.9) | 730 (32.0) | 1.04 | 0.85–1.27 | 0.69 | ||||
Central Obesity | AA | 124 (52.3) | 488 (45.0) | 1.00 | 1.00 | ||||
AG | 98 (41.4) | 479 (44.2) | 0.81 | 0.60–1.08 | 0.15 | 0.77 | 0.56–1.05 | 0.10 | |
GG | 15 (6.3) | 118 (10.8) | 0.50 | 0.28–0.89 | 0.018 | 0.42 | 0.23–0.79 | 0.007 | |
Dominant | 0.75 | 0.56–0.99 | 0.04 | 0.69 | 0.51–0.94 | 0.019 | |||
A | 346 (73.0) | 1455 (67.1) | 1.00 | ||||||
G | 128 (27.0) | 715 (32.9) | 0.75 | 0.60–0.95 | 0.01 |
Variable | Genotype | Case | Control | OR Crude | 95% CI | p | OR Adjusted | 95% CI | p a |
---|---|---|---|---|---|---|---|---|---|
N (%) | N (%) | ||||||||
Overweight | TT | 166 (35.2) | 335 (38.5) | 1.00 | 1.00 | ||||
CT | 233 (49.4) | 390 (44.8) | 1.21 | 0.94–1.54 | 0.14 | 1.22 | 0.93–1.60 | 0.14 | |
CC | 73 (15.4) | 146 (16.7) | 1.01 | 0.72–1.41 | 0.96 | 1.06 | 0.73–1.54 | 0.77 | |
Dominant | 1.15 | 0.91–1.46 | 0.23 | 1.18 | 0.91–1.52 | 0.21 | |||
T | 565 (59.9) | 1060 (60.8) | |||||||
C | 379 (40.1) | 682 (39.2) | 1.04 | 0.88–1.23 | 0.61 | ||||
General Obesity | TT | 50 (43.9) | 335 (38.5) | 1.00 | 1.00 | ||||
CT | 50 (43.9) | 390 (44.8) | 0.86 | 0.57–1.31 | 0.48 | 0.84 | 0.53–1.33 | 0.46 | |
CC | 14 (12.2) | 146 (16.7) | 0.64 | 0.34–1.20 | 0.16 | 0.74 | 0.37–1.45 | 0.38 | |
Dominant | 0.80 | 0.54–1.19 | 0.27 | 0.81 | 0.52–1.25 | 0.34 | |||
T | 150 (65.8) | 1060 (60.8) | |||||||
C | 78 (34.2) | 682 (39.2) | 0.81 | 0.60–1.09 | 0.15 | ||||
Hypertriglyceridemia | TT | 109 (31.7) | 504 (38.6) | 1.00 | 1.00 | ||||
CT | 180 (52.3) | 588 (45.0) | 1.42 | 1.09–1.85 | 0.01 | 1.43 | 1.07–1.90 | 0.015 | |
CC | 55 (16.0) | 215 (16.4) | 1.18 | 0.82–1.70 | 0.36 | 1.18 | 0.80–1.74 | 0.41 | |
Dominant | 1.35 | 1.05–1.74 | 0.019 | 1.36 | 1.04–1.79 | 0.027 | |||
T | 398 (57.8) | 1596 (61.1) | |||||||
C | 290 (42.2) | 1018 (38.9) | 1.14 | 0.96–1.36 | 0.13 | ||||
Borderline-Hypercholesterolemia | TT | 92 (40.9) | 418 (36.7) | 1.00 | 1.00 | ||||
CT | 95 (42.2) | 535 (47.0) | 0.81 | 0.59–1.10 | 0.18 | 0.79 | 0.58–1.09 | 0.15 | |
CC | 38 (16.9) | 186 (16.3) | 0.93 | 0.61–1.41 | 0.73 | 0.93 | 0.61–1.42 | 0.74 | |
Dominant | 0.84 | 0.63–1.12 | 0.24 | 0.83 | 0.62–1.11 | 0.21 | |||
T | 279 (62.0) | 1371 (60.2) | |||||||
C | 171 (38.0) | 907 (39.8) | 0.93 | 0.75–1.15 | 0.47 | ||||
Hypercholesterolemia | TT | 103 (35.9) | 418 (36.7) | 1.00 | 1.00 | ||||
CT | 138 (48.4) | 535 (47.0) | 1.05 | 0.79–1.39 | 0.75 | 1.00 | 0.75–1.35 | 0.99 | |
CC | 46 (16.0) | 186 (16.3) | 1.00 | 0.68–1.48 | 0.99 | 1.00 | 0.67–1.51 | 0.99 | |
Dominant | 1.04 | 0.79–1.36 | 0.80 | 1.00 | 0.76–1.33 | 1.00 | |||
T | 344 (59.9) | 1371 (60.2) | |||||||
C | 230 (40.1) | 907 (39.8) | 1.01 | 0.83–1.22 | 0.91 | ||||
Central Obesity | TT | 93 (39.2) | 406 (37.4) | 1.00 | 1.00 | ||||
CT | 110 (46.4) | 502 (46.3) | 0.96 | 0.71–1.30 | 0.78 | 0.92 | 0.66–1.28 | 0.62 | |
CC | 34 (14.4) | 177 (16.3) | 0.84 | 0.55–1.29 | 0.42 | 0.92 | 0.58–1.46 | 0.72 | |
Dominant | 0.93 | 0.69–1.24 | 0.60 | 0.92 | 0.67–1.25 | 0.58 | |||
T | 296 (62.4) | 1314 (60.6) | |||||||
C | 178 (37.6) | 856 (39.4) | 0.92 | 0.75–1.14 | 0.44 |
Variable | Haplotype | Case | Control | OR | 95% CI | p a |
---|---|---|---|---|---|---|
NO. of Chromosomes (%) | NO. of Chromosomes (%) | |||||
Overweight | AT | 538 (57.0) | 966 (55.5) | Base | ||
GT | 28 (2.9) | 94 (5.4) | 0.55 | 0.35–0.86 | 0.003 | |
AC | 102 (10.8) | 200 (11.5) | 0.92 | 0.71–1.20 | 0.81 | |
GC | 276 (29.3) | 482 (27.7) | 1.03 | 0.86–1.23 | 0.47 | |
General Obesity | AT | 148 (64.8) | 966 (55.5) | Base | ||
GT | 2 (1.0) | 94 (5.4) | 0.17 | 0.04–0.69 | 0.02 | |
AC | 28 (12.4) | 200 (11.5) | 0.93 | 0.61–1.43 | 0.59 | |
GC | 50 (21.8) | 482 (27.7) | 0.67 | 0.48–0.94 | 0.04 | |
Hypertriglyceridemia | AT | 376 (54.7) | 1474 (56.4) | Base | ||
GT | 22 (3.2) | 122 (4.7) | 0.73 | 0.45–1.18 | 0.15 | |
AC | 84 (12.2) | 310 (11.8) | 1.06 | 0.82–1.39 | 0.68 | |
GC | 206 (30.0) | 708 (27.1) | 1.14 | 0.94–1.38 | 0.18 | |
Borderline-hypercholesterolemia | AT | 258 (57.2) | 1270 (55.8) | Base | ||
GT | 22 (4.8) | 100 (4.4) | 1.04 | 0.64–1.70 | 0.74 | |
AC | 52 (11.7) | 278 (12.2) | 0.94 | 0.68–1.29 | 0.75 | |
GC | 118 (26.3) | 630 (27.6) | 0.93 | 0.73–1.18 | 0.57 | |
Hypercholesterolemia | AT | 322 (56.0) | 1270 (55.8) | Base | ||
GT | 22 (3.9) | 100 (4.4) | 0.90 | 0.56–1.44 | 0.72 | |
AC | 64 (11.1) | 278 (12.2) | 0.91 | 0.68–1.23 | 0.50 | |
GC | 166 (29.0) | 630 (27.6) | 1.05 | 0.85–1.29 | 0.57 | |
Central Obesity | AT | 290 (61.0) | 1212 (55.9) | Base | ||
GT | 6 (1.5) | 102 (4.7) | 0.31 | 0.14–0.71 | 0.006 | |
AC | 56 (12.0) | 242 (11.2) | 0.98 | 0.72–1.34 | 0.46 | |
GC | 122 (25.6) | 614 (28.3) | 0.82 | 0.65–1.04 | 0.20 |
3. Discussion
4. Experimental Section
4.1. Subjects
4.2. Selection of Single Nucleotide Polymorphisms and Genotyping
4.3. Statistical Analysis
5. Conclusions
Supplementary Files
Supplementary File 1Acknowledgments
Author Contributions
Conflicts of Interest
References
- Calle, E.E.; Kaaks, R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4, 579–591. [Google Scholar] [CrossRef]
- Aaronson, D.S.; Horvath, C.M. A road map for those who don’t know JAK–STAT. Science 2002, 296, 1653–1655. [Google Scholar] [CrossRef]
- Vaisse, C.; Halaas, J.L.; Horvath, C.M.; Darnell, J.E., Jr.; Stoffel, M.; Friedman, J.M. Leptin activation of STAT3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat. Genet. 1996, 14, 95–97. [Google Scholar] [CrossRef]
- Bates, S.H.; Stearns, W.H.; Dundon, T.A.; Schubert, M.; Tso, A.W.; Wang, Y.; Banks, A.S.; Lavery, H.J.; Haq, A.K.; Maratos-Flier, E.; et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003, 421, 856–859. [Google Scholar] [CrossRef]
- Cui, Y.; Huang, L.; Elefteriou, F.; Yang, G.; Shelton, J.M.; Giles, J.E.; Oz, O.K.; Pourbahrami, T.; Lu, C.Y.H.; Richardson, J.A.; et al. Essential role of STAT3 in body weight and glucose homeostasis. Mol. Cell. Biol. 2003, 24, 258–269. [Google Scholar]
- Gao, Q.; Wolfgang, M.J.; Neschen, S.; Morino, K.; Horvath, T.L.; Shulman, G.I.; Fu, X.Y. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc. Natl. Acad. Sci. USA 2004, 101, 4661–4666. [Google Scholar]
- Gorogawa, S.; Fujitani, Y.; Kaneto, H.; Hazama, Y.; Watada, H.; Miyamoto, Y.; Takeda, K.; Akira, S.; Magnuson, M.A.; Yamasaki, Y.; et al. Insulin secretory defects and impaired islet architecture in pancreatic β-cell-specific STAT3 knockout mice. Biochem. Biophys. Res. Commun. 2004, 319, 1159–1170. [Google Scholar] [CrossRef]
- Cernkovich, E.R.; Deng, J.; Bond, M.C.; Combs, T.P.; Harp, J.B. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity. Endocrinology 2008, 149, 1581–1590. [Google Scholar] [CrossRef]
- Inoue, H.; Ogawa, W.; Ozaki, M.; Haga, S.; Matsumoto, M.; Furukawa, K.; Hashimoto, N.; Kido, Y.; Mori, T.; Sakaue, H.; et al. Role of STAT3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10, 168–174. [Google Scholar] [CrossRef]
- Inoue, H.; Ogawa, W.; Asakawa, A.; Okamoto, Y.; Nishizawa, A.; Matsumoto, M.; Teshigawara, K.; Matsuki, Y.; Watanabe, E.; Hiramatsu, R.; et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006, 3, 267–275. [Google Scholar] [CrossRef]
- Derecka, M.; Gornicka, A.; Koralov, S.B.; Szczepanek, K.; Morgan, M.; Raje, V.; Sisler, J.; Zhang, Q.F.; Otero, D.; Cichy, J.; et al. Tyk2 and STAT3 regulate brown adipose tissue differentiation and obesity. Cell Metab. 2012, 16, 814–824. [Google Scholar] [CrossRef]
- Jamshidi, Y.; Kyriakou, T.; Gooljar, S.B.; Collins, L.J.; Lane, C.A.; Snieder, H.; Wang, X.; Spector, T.D.; O’Dell, S.D. Common STAT3 variants are not associated with obesity or insulin resistance in female twins. Obesity 2007, 15, 1634–1639. [Google Scholar] [CrossRef]
- Gianotti, T.F.; Sookoian, S.; Gemma, C.; Burgueno, A.L.; Gonzalez, C.D.; Pirola, C.J. Study of genetic variation in the STAT3 on obesity and insulin resistance in male adults. Obesity 2008, 16, 1702–1707. [Google Scholar] [CrossRef]
- Phillips, C.M.; Goumidi, L.; Bertrais, S.; Field, M.R.; Peloso, G.M.; Shen, J.; McManus, R.; Hercberg, S.; Lairon, D.; Planells, R.; et al. Dietary saturated fat modulates the association between STAT3 polymorphisms and abdominal obesity in adults. J. Nutr. 2009, 139, 2011–2017. [Google Scholar] [CrossRef]
- Li, P.; Tiwari, H.K.; Lin, W.Y.; Allison, D.B.; Chung, W.K.; Leibel, R.L.; Yi, N.; Liu, N. Genetic association analysis of 30 genes related to obesity in a European American population. Int. J. Obes. 2014. [Google Scholar] [CrossRef]
- Kinoshita, S.O.W.; Okamoto, Y.; Takashima, M.; Inoue, H.; Matsuki, Y.; Watanabe, E.; Hiramatsu, R.; Kasuga, M. Role of hepatic STAT3 in the regulation of lipid metabolism. Kobe J. Med. Sci. 2008, 54, E200–E208. [Google Scholar]
- Elam, M.B.; Yellaturu, C.; Howell, G.E.; Deng, X.; Cowan, G.S.; Kumar, P.; Park, E.A.; Hiler, M.L.; Wilcox, H.G.; Hughes, T.A.; et al. Dysregulation of sterol regulatory element binding protein-1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription-1 signaling. Metabolism 2010, 59, 587–598. [Google Scholar] [CrossRef]
- Horiguchi, A.; Asano, T.; Asano, T.; Ito, K.; Sumitomo, M.; Hayakawa, M. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J. Urol. 2008, 180, 729–736. [Google Scholar] [CrossRef]
- Miller, A.M.; Wang, H.; Bertola, A.; Park, O.; Horiguchi, N.; Ki, S.H.; Yin, S.; Lafdil, F.; Gao, B. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011, 54, 846–856. [Google Scholar] [CrossRef]
- Bhatnagar, S.; Damron, H.A.; Hillgartner, F.B. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 2009, 284, 10023–10033. [Google Scholar] [CrossRef]
- Miranda, K.C.; Huynh, T.; Tay, Y.; Ang, Y.S.; Tam, W.L.; Thomson, A.M.; Lim, B.; Rigoutsos, I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126, 1203–1217. [Google Scholar] [CrossRef]
- Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef]
- Fetting, J.L.; Guay, J.A.; Karolak, M.J.; Iozzo, R.V.; Adams, D.C.; Maridas, D.E.; Brown, A.C.; Oxburgh, L. FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney. Development 2014, 141, 17–27. [Google Scholar] [CrossRef]
- Takahashi, H.; Sakuta, H.; Shintani, T.; Noda, M. Functional mode of FoxD1/CBF2 for the establishment of temporal retinal specificity in the developing chick retina. Dev. Biol. 2009, 331, 300–310. [Google Scholar] [CrossRef]
- Expert Panel on Detection, E. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285, 2486–2497. [Google Scholar] [CrossRef]
- Chen, C.; Lu, F.C. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed. Environ. Sci. 2004, 17, 1–36. [Google Scholar]
- Alberti, K.G.; Zimmet, P.; Shaw, J. The metabolic syndrome—A new worldwide definition. Lancet 2005, 366, 1059–1062. [Google Scholar] [CrossRef]
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Ma, Z.; Wang, G.; Chen, X.; Ou, Z.; Zou, F. Association of STAT3 Common Variations with Obesity and Hypertriglyceridemia: Protective and Contributive Effects. Int. J. Mol. Sci. 2014, 15, 12258-12269. https://doi.org/10.3390/ijms150712258
Ma Z, Wang G, Chen X, Ou Z, Zou F. Association of STAT3 Common Variations with Obesity and Hypertriglyceridemia: Protective and Contributive Effects. International Journal of Molecular Sciences. 2014; 15(7):12258-12269. https://doi.org/10.3390/ijms150712258
Chicago/Turabian StyleMa, Zuliang, Guanghai Wang, Xuejiao Chen, Zejin Ou, and Fei Zou. 2014. "Association of STAT3 Common Variations with Obesity and Hypertriglyceridemia: Protective and Contributive Effects" International Journal of Molecular Sciences 15, no. 7: 12258-12269. https://doi.org/10.3390/ijms150712258